Top Markets
Coin of the day
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Ранг среди акций #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Цена акции
$2.72
Последняя синхронизация: 2023-10-19
Рыночная капитализация
$111.47M
Изменение (1 день)
-0.73%
Изменение (1 год)
0.00%
Страна
US
Торговля Talaris Therapeutics, Inc. (TALS)

Категория

История дивидендной доходности для Talaris Therapeutics, Inc. (TALS)
Дивидендная доходность (TTM) компании Talaris Therapeutics, Inc. (тикер: TALS) на 2026 составляет: 0
Средняя дивидендная доходность за последние 5 лет: 0.00%
История дивидендной доходности компании Talaris Therapeutics, Inc. (TALS) с 2026 по 2026
Дивидендная доходность на конец каждого года (TTM)
Год Дивидендная доходность Изменить
Недостаточно данных для указанных дат.
Дивидендная доходность (TTM) аналогичных компаний или конкурентов
Компания Дивидендная доходность Страна
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH